A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design

导出原文传递

翻译打印收藏纠错

作者： Passiglia, Francesco ^[1] ; Bironzo, Paolo ; Righi, Luisella ; Listi, Angela ; Arizio, Francesca ; Novello, Silvia ; Volante, Marco ; Scagliotti, Giorgio Vittorio

作者单位： Univ Turin, S Luigi Gonzaga Hosp, Dept Oncol, Reg Gonzole 10, I-10034 Orbassano, TO, Italy ^[1]

关键词 Homologous recombination repair deficiency PD-L1 PARP inhbitors PD-1 inhibitors Treatment combinations

发布时间 2021-04-27

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical lung cancer

2021年22卷1期

E63-E66页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design

Clinical lung cancer

相似文献

Clinical lung cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design

Clinical lung cancer

相似文献

Clinical lung cancer

相关期刊

检索历史清除